SHC Stock Overview
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Sotera Health Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.64 |
52 Week High | US$19.40 |
52 Week Low | US$10.71 |
Beta | 2.09 |
1 Month Change | 5.63% |
3 Month Change | -18.20% |
1 Year Change | -22.24% |
3 Year Change | -54.14% |
5 Year Change | n/a |
Change since IPO | -53.63% |
Recent News & Updates
Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 30The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%
Mar 21Recent updates
Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 30The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%
Mar 21Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models
Mar 01McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount
Feb 08Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Feb 06Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump
Dec 28Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price
Dec 11An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued
Sep 10Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jun 05Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?
Feb 13Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher
Nov 24Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit
Sep 19Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?
Sep 08Sotera Health GAAP EPS of $0.11 misses by $0.05, revenue of $266.64M beats by $10.34M
Aug 04Is Sotera Health Company (NASDAQ:SHC) Trading At A 46% Discount?
May 09Returns On Capital Are Showing Encouraging Signs At Sotera Health (NASDAQ:SHC)
Mar 16Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 38%?
Jan 19Shareholder Returns
SHC | US Life Sciences | US Market | |
---|---|---|---|
7D | 5.4% | -1.6% | -0.6% |
1Y | -22.2% | 3.7% | 21.7% |
Return vs Industry: SHC underperformed the US Life Sciences industry which returned 4% over the past year.
Return vs Market: SHC underperformed the US Market which returned 22.4% over the past year.
Price Volatility
SHC volatility | |
---|---|
SHC Average Weekly Movement | 5.4% |
Life Sciences Industry Average Movement | 6.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SHC's share price has been volatile over the past 3 months.
Volatility Over Time: SHC's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Sotera Health Company Fundamentals Summary
SHC fundamental statistics | |
---|---|
Market cap | US$3.24b |
Earnings (TTM) | US$54.57m |
Revenue (TTM) | US$1.08b |
60.4x
P/E Ratio3.1x
P/S RatioIs SHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SHC income statement (TTM) | |
---|---|
Revenue | US$1.08b |
Cost of Revenue | US$484.10m |
Gross Profit | US$592.77m |
Other Expenses | US$538.20m |
Earnings | US$54.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.19 |
Gross Margin | 55.05% |
Net Profit Margin | 5.07% |
Debt/Equity Ratio | 519.2% |
How did SHC perform over the long term?
See historical performance and comparison